ABBV-453

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor ABBV-453 Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma

Arms / Cohorts

Experimental:Substudy 1: Dose Escalation ABBV-453 Combination

Accepting patients

Experimental:Substudy 1: Dose Expansion and Selection ABBV-453 Combination

Accepting patients

Active Comparator:Substudy 1: Dose Expansion and Selection Control

Accepting patients

Experimental:Substudy 2: Dose Escalation ABBV-453 Monotherapy

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.